2024-03-29T12:52:36Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00027963
2023-01-16T04:43:45Z
499:500:501
Serum cystatin C level is associated with locomotive syndrome risk and can be an early predictor in community-living people: The Yakumo study
Tanaka, Satoshi
Ando, Kei
Kobayashi, Kazuyoshi
Hida, Tetsuro
Ito, Kenyu
Tsushima, Mikito
Morozumi, Masayoshi
Machino, Masaaki
Ota, Kyotaro
Seki, Taisuke
Suzuki, Koji
Nishida, Yoshihiro
Ishiguro, Naoki
Hasegawa, Yukiharu
Imagama, Shiro
open access
This is an Accepted Manuscript of an article published by Taylor & Francis Group in Modern Rheumatology on 02/05/2018, available online: http://www.tandfonline.com/10.1080/14397595.2018.1441675.
community-living people
health checkup
locomotive syndrome risk
serum cystatin C
Objectives: The locomotive syndrome (LS) risk has been recently proposed as a criterion for evaluating physical ability. Serum cystatin C level is an early renal function marker and a cardiovascular disease predictor. This study aimed to evaluate the relationship between serum cystatin C level and LS risk. Methods: We enrolled 54 participants and conducted the two-step test, stand-up test, 25-question geriatric locomotive function scale, LS risk test, Timed Up and Go test, back muscle strength, grip strength, blood test and serum cystatin C level measurement. A comparative study was conducted in participants with and without LS risk and in subgroups aged <60 and ≥60 years. Results: No significant difference was found in the serum cystatin C level in subgroups aged <60 years and without LS risk. However, it was significantly higher in subjects with LS risk and aged ≥60 years. The area under the curve of the serum cystatin C level for LS risk was 0.824. Conclusion: The serum cystatin C level is significantly related to LS risk and can be an early predictor. In middle-aged and elderly people with high serum cystatin C levels, it is strongly recommended to enforce LS risk test and intervention.
Published online: 02 Mar 2018
Taylor & Francis
2018
eng
journal article
AM
http://hdl.handle.net/2237/00030161
https://nagoya.repo.nii.ac.jp/records/27963
https://doi.org/10.1080/14397595.2018.1441675
1439-7595
Modern Rheumatology
28
6
1035
1040
https://nagoya.repo.nii.ac.jp/record/27963/files/cystatin_LS risk_MORH.pdf
application/pdf
1.5 MB
2019-05-10